Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab vs PVd or Kd in Relapsed/Refractory Multiple Myeloma
NCT05572515Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of teclistamab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free Survival up to 9 years and Cytokine Release Syndrome up to 9 years. Started Mar 2023; status: active, not recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05572515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05572515.